Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma

Chikuie, Nobuyuki; Urabe, Yuji; Ueda, Tsutomu; Hamamoto, Takao; Taruya, Takayuki; Kono, Takashi; Yumii, Kohei; Takeno, Sachio

doi:10.1038/s41598-022-13417-5

Cited by 11 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the few studies using tumor‐derived ctDNA in head and neck oncology published by Chikuie et al 22 studied its utility in cancer surveillance. Their study included 20 patients and they reported the presence of ctDNA in 5 out of the 7 patients that had a recurrence.…”

Section: Discussionmentioning

confidence: 99%

ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment

Lele,

Adilbay,

Lewis

et al. 2024

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

ObjectiveCirculating tumor DNA (ctDNA) detection is an emerging technique that identifies minimal residual disease in patients with solid tumors. ctDNA can act as an adjunct method to help overcome the limitations of positron emission tomography (PET) and select patients who are at high risk for recurrence.Study DesignRetrospective Single Institutional Study.SettingUniversity Hospital Setting.MethodsTwenty‐nine patients who underwent definitive treatment for squamous cell carcinoma of the head and neck (HNSCC) from 8/2021 to 01/2023 had ctDNA levels analyzed at 1 to 3, 6, 9, and 12 months after definitive treatment. A personalized, tumor‐informed, multiplex polymerase chain reaction (PCR) next‐generation sequencing (NGS) assay was used to detect the ctDNA levels. The primary outcome was recurrence‐free probability (RFP), and the secondary outcomes were overall survival (OS), sensitivity, specificity, and the test's negative (NPV) and positive predictive values (PPV).ResultsThe median age of patients was 65 years (interquartile range: 56‐69), with majority being males (n = 22, 76%). The primary sites were larynx (n = 12), oropharynx (n = 10), and oral cavity (n = 6). Posttreatment ctDNA was detected in 7 patients, all of whom had disease recurrence. ctDNA detection after definitive treatment was associated with a higher risk of disease recurrence (hazard ratio: 9.94, 95% confidence interval: 1.56‐63.3, P = .015). ctDNA identified recurrence with 100% specificity and 78% sensitivity. The NPV and PPV were 91% and 100%. PET had 78% sensitivity but only 68% specificity with 86% NPV, and 54% PPV.ConclusionBased on our data, ctDNA can be an excellent adjunct test for posttreatment PET and can help guide physicians in cases where PET results are inconclusive and difficult to interpret.

show abstract

Section: Discussionmentioning

confidence: 99%

ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment

Lele,

Adilbay,

Lewis

et al. 2024

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

show abstract

“…52 Studies have shown that ctDNA levels are elevated in patients with HNC and can be used to monitor disease progression and response to treatment. 53 In addition, ctDNA has been found to be a prognostic marker, with higher levels associated with poorer outcomes. The use of liquid biomarkers in HNC is still in the early stages of development, and more research is needed to determine their clinical utility.…”

Section: Surveillance/survivorshipmentioning

confidence: 99%

“…Several liquid biomarkers have been identified in HNC, including circulating tumor cells, cell-free tumor DNA (ctDNA), proteins, metabolites, exosomes, messenger RNA (mRNA), and micro RNAs (miRNAs) 52 . Studies have shown that ctDNA levels are elevated in patients with HNC and can be used to monitor disease progression and response to treatment 53 . In addition, ctDNA has been found to be a prognostic marker, with higher levels associated with poorer outcomes.…”

Section: Surveillance/survivorshipmentioning

confidence: 99%

Overview of head and neck cancer and the role of survivorship care

Fazer-Posorske,

Guenzel,

McGrath

et al. 2024

Journal of Dermatology for Physician Assistants

View full text Add to dashboard Cite

Head and neck cancer (HNC) accounted for 4% of all malignancies in 2022 and is often associated with tobacco and alcohol use, but the incidence of human papillomavirus (HPV)–associated HNC has steadily increased in recent decades. Unlike HPV-negative HNC, HPV-positive HNC has a favorable prognosis and survival is significantly better resulting in a large population of HNC survivors. Survivorship for HNC is of the utmost importance as there is a high burden of side effects that impact function and quality of life, and the patients with HPV HNC are living longer with the sequelae of their treatment.

show abstract

Targeting Molecular Residual Disease Using Novel Technologies and Clinical Trials Design in Head and Neck Squamous Cell Cancer

Sanz-García

Siu

2023

Critical Issues in Head and Neck Oncology

View full text Add to dashboard Cite

High-risk human papillomavirus (HPV)-related and most cases of HPV-negative locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC) have substantial risks of relapse despite definitive therapy, and thus represent conditions of unmet clinical need. The ability now exists to detect molecular residual disease (MRD) in these patients post-definitive treatment such as surgery or (chemo)radiotherapy using novel and highly sensitive and specific technologies to measure cancer-derived circulating biomarkers. The positive and negative predictive values of these assays to forecast cancer recurrence, as well as the lead time of circulating tumor DNA (ctDNA) detection before clinical relapse, are relevant as these parameters rationalize the design of clinical trials for cancer interception in the MRD setting. Currently, there is evidence that interception in the MRD setting yields benefit in clinical outcome in some cancers, but such data do not yet exist in LA-HNSCC and will require prospective testing via clinical trials.

show abstract

Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma

Cited by 11 publications

References 36 publications

ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment

ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment

Overview of head and neck cancer and the role of survivorship care

Targeting Molecular Residual Disease Using Novel Technologies and Clinical Trials Design in Head and Neck Squamous Cell Cancer

Contact Info

Product

Resources

About